CN111012863A - 一种麦冬降解提取物及其在制备降糖药物中的应用 - Google Patents
一种麦冬降解提取物及其在制备降糖药物中的应用 Download PDFInfo
- Publication number
- CN111012863A CN111012863A CN201911332830.3A CN201911332830A CN111012863A CN 111012863 A CN111012863 A CN 111012863A CN 201911332830 A CN201911332830 A CN 201911332830A CN 111012863 A CN111012863 A CN 111012863A
- Authority
- CN
- China
- Prior art keywords
- extract
- degradation
- polysaccharide
- ophiopogon
- crude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015556 catabolic process Effects 0.000 title claims abstract description 38
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003472 antidiabetic agent Substances 0.000 title description 3
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 150000004676 glycans Chemical class 0.000 claims abstract description 46
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 42
- 239000005017 polysaccharide Substances 0.000 claims abstract description 42
- 210000004369 blood Anatomy 0.000 claims abstract description 30
- 239000008280 blood Substances 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000706 filtrate Substances 0.000 claims abstract description 15
- 238000001914 filtration Methods 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000007857 degradation product Substances 0.000 claims abstract description 7
- 230000000593 degrading effect Effects 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 239000002244 precipitate Substances 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 6
- 238000001704 evaporation Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 4
- 239000011344 liquid material Substances 0.000 claims abstract description 3
- 229930195210 Ophiopogon Natural products 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 10
- 230000001376 precipitating effect Effects 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- 230000003544 deproteinization Effects 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003859 lipid peroxidation Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000002000 scavenging effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- 229960001031 glucose Drugs 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 235000020828 fasting Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000001728 nano-filtration Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 150000004804 polysaccharides Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000020927 12-h fasting Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241001448424 Ophiopogon Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
Abstract
本发明公开一种具有更高降糖活性的麦冬降解提取物。制备方法为:药材按液料比5~20,水提取1~3次,每次提取0.5~2小时,滤过,滤液浓缩至原料含量为0.5~2g/ml的浸膏,加乙醇使含醇量达75%~90%,沉淀蒸干得麦冬粗多糖;采用Sevage法脱蛋白纯化;纯化后加水充分溶解至透明状态,按料液比10:1加入2mol/L的酸,降解4~6h,加碱溶液至中性,超滤截留得分子量范围在500-2500之间的降解物,浓缩冷冻干燥,即得。与现有技术相比,本提取物在降血糖方面具有更高的活性,明显优于麦冬粗多糖及其他现有方法获得的麦冬小分子多糖。产率可以高达95%以上,且方法简单易行,可规模化生产。
Description
技术领域
本发明涉及一种麦冬降解提取物及其在制备降糖药物中的应用。
背景技术
麦冬为百合科植物麦冬Ophiopogon japonicus(L.f)Ker-Gawl的干燥块根。麦冬为传统滋阴中药之一,其味甘、微苦,性微寒,归心、肺、胃经,有养阴生津,润肺清心的功效,用于肺燥干咳、虚痨咳嗽、津伤口渴、心烦失眠、内热消渴、肠燥便秘。麦冬的活性成分主要有甾体皂苷、多糖、高异黄酮类等。
药理及临床试验研究表明,从麦冬中提取得到的粗多糖能有效的降低实验性糖尿病小鼠的血糖水平,降低II型糖尿病患者空腹血糖和餐后2h血糖水平,改善胰岛素抵抗。
多糖的活性主要由分子质量决定,分子质量较小的多糖活性更高,更容易被人体吸收利用。麦冬多糖常规提取方法为水提醇沉法,得到的麦冬多糖分子质量较大。现有技术制备小分子麦冬多糖采用超滤法,大于10000分子量的多糖被过滤除去,通过多糖的降解,使大分子多糖变成小分子多糖,多糖可以得到充分的利用,并且活性增加。
为了用较简便易行的方法得到分子质量较小的低聚麦冬多糖,我们采用化学降解法,进行多糖分子的降解,得到活性更强的小分子多糖。
发明内容
本发明的目的为提供一种具有更高活性的麦冬降解提取物,且制备方法简单易行。
本发明的麦冬降解提取物由以下方法制备,包括以下步骤:
1.提取麦冬粗多糖:将麦冬药材按液料比5~20,加水提取1~3次,每次提取0.5~2小时,滤过,滤液浓缩至原料含量为0.5~2g/ml的浸膏,加乙醇使含醇量达75%~90%,静置,取沉淀蒸干得到麦冬粗多糖;
2.脱蛋白:麦冬粗多糖采用Sevage法脱蛋白纯化;
3.降解:将步骤(2)所述麦冬多糖加水充分溶解至透明状态,以麦冬药材的质量计,按料液比10:1加入2mol/L的酸,降解4~6h,加入NaOH溶液中和至中性,超滤截留得分子量范围在500-2500之间的降解物,浓缩冷冻干燥,即得麦冬降解提取物。
其中,步骤1工艺优选为:将麦冬药材加水提取2次,液料比10,每次提取2小时,滤过,合并滤液,滤液浓缩至原料含量为1g/ml的浸膏,加乙醇使含醇量达80%,静置过夜;滤去上清液,沉淀蒸干得到麦冬粗多糖。
步骤3所述的酸优选盐酸或硫酸,降解温度优选50℃~100℃,最优为50℃。
步骤2优选工艺为:取麦冬粗多糖,加蒸馏水溶解,加入三氯甲烷:正丁醇(4:1),搅拌充分溶解,分液漏斗静置,取下层液于高速离心机5000r/min离心10分钟,除沉淀,清液经乙醇沉淀,干燥,得纯化的麦冬多糖。
与现有技术相比,本发明具有如下有益效果:本发明的降解提取物在降血糖方面具有更高的活性,明显优于麦冬粗多糖及其他现有方法获得的麦冬小分子多糖。产率可以高达 98%以上,且方法简单易行,可规模化生产。
具体实施方式
以下通过具体实施例对本发明作进一步说明。
实施例1:
取麦冬药材5000克,加水煎煮提取1次,加水20倍量,煎煮2小时,滤过,合并滤液,滤液浓缩至原料含量为1g/ml的浸膏,加入乙醇至含醇量为80%,放置过夜,沉淀经过滤干燥后得到麦冬粗多糖。麦冬粗多糖溶液采用Sevage法脱蛋白,乙醇沉淀,干燥,得纯化的麦冬多糖;将纯化后的麦冬多糖加水充分溶解至透明状态,加入2mol/L硫酸500ml,50℃降解4个时,加入NaOH溶液中和至中性,降解液经超滤截留分子量10000 以下的降解物,超滤液再采用纳滤技术进行浓缩,浓缩液经冷冻干燥,即得麦冬降解提取物。
实施例2:
取麦冬药材5000克,加水煎煮提取2次,加水10倍量,煎煮2小时,滤过,合并滤液,滤液浓缩至原料含量为1.5g/ml的浸膏,加入乙醇至含醇量为85%,放置过夜,沉淀经过滤干燥后得到麦冬粗多糖。麦冬粗多糖溶液采用Sevage法脱蛋白,乙醇沉淀,干燥,得纯化的麦冬多糖;将纯化后的麦冬多糖加水充分溶解至透明状态,加入2mol/L 盐酸500ml,70℃降解5个时,加入NaOH溶液中和至中性,降解液经超滤截留分子量10000 以下的降解物,超滤液再采用纳滤技术进行浓缩,浓缩液经冷冻干燥,即得麦冬降解提取物。
实施例3:
取麦冬药材5000克,加水煎煮提取1次,加水20倍量,煎煮2小时,滤过,合并滤液,滤液浓缩至原料含量为1g/ml的浸膏,加入乙醇至含醇量为80%,放置过夜,沉淀经过滤干燥后得到麦冬粗多糖。麦冬粗多糖溶液采用Sevage法脱蛋白,乙醇沉淀,干燥,得纯化的麦冬多糖;将纯化后的麦冬多糖加水充分溶解至透明状态,加入2mol/L硫酸500 ml,80℃降解3个时,加入NaOH溶液中和至中性,降解液经超滤截留分子量10000以下的降解物,超滤液再采用纳滤技术进行浓缩,浓缩液经冷冻干燥,即得麦冬降解提取物。
实施例4:
取麦冬药材5000克,加水煎煮提取2次,加水5倍量,煎煮1小时,滤过,合并滤液,滤液浓缩至原料含量为0.5g/ml的浸膏,加入乙醇至含醇量为75%,放置过夜,沉淀经过滤干燥后得到麦冬粗多糖。麦冬粗多糖溶液采用Sevage法脱蛋白,乙醇沉淀,干燥,得纯化的麦冬多糖;将纯化后的麦冬多糖加水充分溶解至透明状态,加入2mol/L 盐酸500ml,100℃降解1个时,加入NaOH溶液中和至中性,降解液经超滤截留分子量10000 以下的降解物,超滤液再采用纳滤技术进行浓缩,浓缩液经冷冻干燥,即得麦冬降解提取物。
实施例5:
麦冬降解提取物多糖含量的测定:采用硫酸蒽酮法测定多糖含量
(1)标准溶液的配制:
取经105℃干燥至恒重的无水葡萄糖对照品33mg,精密称定,置100ml量瓶中,加水溶解并稀释至刻度,摇匀,即得。
(2)标准曲线的制备
标准曲线的制备精密量取对浑品溶液0.1ml、0.2ml、0.3ml、0.4ml、0.5ml、 0.6ml,分别置10ml具塞刻度试管中,各加水至2.0ml,摇匀,在冰水浴中缓缓滴加 0.2%蒽酮-硫酸溶液至刻度,混匀,放冷后置水浴中保温10分钟,取出,立即置冰水浴中冷却10分钟,取出,以相应试剂为空白。照紫外-可见分光光度法,在582nm波长处测定吸光度。以吸光度为纵坐标,浓度为横坐标,绘制标准曲线。
(3)样品溶液的制备
精密称取降解提取物约10mg,加水溶解后转移至50ml容量瓶中,加水至刻度,摇匀。
(4)样品测定
精密吸取样品溶液0.1ml,按“标准曲线制备”项下操作,测得样品的吸光度值,计算含量。
测得麦冬降解提取物中糖的含量,其中实施例1的糖含量大于98%,实施例2的糖含量为97%,实施例3和4的糖含量为95%。
实施例6:
麦冬降解提取物分子量范围的测定:将各麦冬降解提取物配成2μg/ml溶液,分别取 0.5ul样品溶液与5mg/ml的基质2,5-二羟基苯甲酸(DHB)互溶挥干溶液,MALDI-TOF-MASS 进样检测,结果测得麦冬降解提取物的分子量范围圴在500-2500之间。
实施例7:
麦冬降解提取物(实施例4)对实验性II型糖尿病大鼠的作用
(1)动物分组:健康Wistar大鼠(SPF级),雄性,体重180-220g(由南方医科大学实验动物中心提供),自由饮水进食,随机分为正常对照组和造模组,造模组按如下方法建立模型,造模成功后再将模型组动物随机分为模型对照组、阳性药物组、并设相对应剂量的麦冬粗多糖组、麦冬降解提取物组,给药方式同前。连续给药1周。
(2)大鼠模型制备:正常组大鼠每天灌胃普通饮用水,高脂组大鼠每天早晚灌胃自制脂肪乳(1ml/100gBW)。连续灌胃脂肪乳2周后,动物禁食不禁水24h,空白对照组10只尾静脉注射生理盐水,其余大鼠均尾静脉注射30mg/kgBW链脲佐菌素溶液(临用前配制)。给药48h后,禁食不禁水12h,每隔3小时眼眶静脉丛取血,按照血糖测定试剂盒操作测定空腹血糖值,连续测定3次,空腹血糖值≧16.7mmol/L的为造模成功大鼠。
(3)血糖测定:末次给药后,动物禁食不禁水12h,眼眶静脉丛取血,按照试剂盒的方法分别测定血糖值。采用SPSS11.0统计软件,分析并比较各组血糖值及给药前后血糖值的变化情况,结果见表1。
表1给药后血糖值比较
注:*P<0.05vs模型组**P<0.01vs模型组ΔP<0.05vs同组给药前ΔΔP<0.01vs同组给药前
(4)口服葡萄糖耐量实验
连续给药7天后,动物禁食不禁水12h,眼眶静脉丛取血测定血糖值。各组均ig. 葡萄糖2.0g/kgBW,分别在给予葡萄糖后0.5h、1h、2h,从眼眶静脉丛采血,按血糖试剂盒的方法测定血糖值,结果见表2。
表2口服糖耐量实验
注:*P<0.05vs模型组**P<0.01vs模型组
以上结果说明麦冬粗多糖高剂组具有降血糖作用;麦冬降解提取物高、中、低剂量组均具有降血糖的作用,其中高、中剂量组具有极显著意义(P<0.01),麦冬降解提取物组的降血糖效果优于麦冬粗多糖组。
实施例8:麦冬降解提取物(实施例4)对四氧嘧啶诱导的糖尿病小鼠的作用
(1)健康昆明种小鼠(SPF级),雌雄各半,体重18~20g(由南方医科大学实验动物中心提供)。
(2)糖尿病小鼠造模:采用四氧嘧啶(ALX)致小鼠高血糖模型的方法,取小鼠(雌雄各半)禁食(不禁水)12h后,分别腹腔注射2%的新鲜ALX溶液(220mg/kg)2次(第1 次注射量为总量的70%,第2次为总量的30%,两次间隔12h)。3天后,禁食12h后断尾取血,用血糖试纸及测试仪测定小鼠血糖,并测定体重。FPG>11.1mmol/L,定为糖尿病模型小鼠。
(3)检测指标:在实验期观察小鼠的采食、饮水、体质量、精神状态、毛色等状况;分别在给药后的2h、3d、14d断尾取血测定小鼠禁食12h后的血糖值,实验结束时测定小鼠禁食12h后的血清胰岛素。采用SPSS11.0统计软件进行数据分析。
(4)麦冬降解提取物对四氧嘧啶糖尿病小鼠空腹血糖的影响
用四氧嘧啶造模后的小鼠出现了多饮、多食、多尿、体重减轻,并有反应迟钝,被毛杂乱无光等症状,在用药后各组小鼠以上症状均有不同程度的改善,反应较灵活,毛平伏且有光泽。对四氧嘧啶糖尿病小鼠在灌胃麦冬降解提取物后2h、3d和14d后与模型组比较,中、高剂量组能极显著地降低小鼠的血糖值(P<0.01),麦冬降解提取物组优于麦冬粗多糖组。结果见表3.
表3麦冬降解提取物对四氧嘧啶糖尿病小鼠空腹血糖的影响
注:与模型组比较,*P<0.05,**P<0.01
(5)麦冬降解提取物对糖尿病小鼠血清胰岛素水平的影响
连续灌服麦冬降解提取物14d后,与模型组比较小鼠血清胰岛素水平有显著升高,其中高、中剂量给具有极显著意义(**P<0.01),并有剂量-效应关系,麦冬降解提取物效果优于麦冬粗多糖组,见表4。
表4.麦冬降解提取物对糖尿病小鼠血清胰岛素水平的影响
注:与模型组比较,*P<0.05,**P<0.01。
Claims (8)
1.一种麦冬降解提取物,其特征在于由以下方法制备:
(1)提取麦冬粗多糖:将麦冬药材按液料比5~20,加水提取1~3次,每次提取0.5~2小时,滤过,滤液浓缩至原料含量为0.5~2g/ml的浸膏,加乙醇使含醇量达75%~90%,静置,取沉淀蒸干得到麦冬粗多糖;
(2)脱蛋白:麦冬粗多糖采用Sevage法脱蛋白纯化;
(3)降解:将步骤(2)所述麦冬多糖加水充分溶解至透明状态,以麦冬药材的质量计,按料液比10:1加入2mol/L的酸,降解4~6h,加入NaOH溶液中和至中性,超滤截留得分子量范围在500-2500之间的降解物,浓缩冷冻干燥,即得麦冬降解提取物。
2.根据权利要求1所述的提取物,其特征在于步骤(1)具体为:将麦冬药材加水提取2次,液料比10,每次提取2小时,滤过,合并滤液,滤液浓缩至原料含量为1g/ml的浸膏,加乙醇使含醇量达80%,静置过夜;滤去上清液,沉淀蒸干得到麦冬粗多糖。
3.根据权利要求1所述的提取物,其特征在于步骤(3)具体为:所述的酸是盐酸或硫酸,降解温度为50℃~100℃。
4.根据权利要求3所述的提取物,其特征在于步骤(3)具体为:所述的酸降解温度为50℃,降解时间为4小时。
5.根据权利要求1所述的提取物,其特征在于步骤(2)具体为:取麦冬粗多糖,加蒸馏水溶解,加入三氯甲烷:正丁醇(4:1),搅拌充分溶解,分液漏斗静置,取下层液于高速离心机5000r/min离心10分钟,除沉淀,清液经乙醇沉淀,干燥,得纯化的麦冬多糖。
6.权利要求1到5所述的任一提取物在制备降血脂药物中的应用。
7.权利要求1到5所述的任一提取物在制备清除体内自由基,防止细胞脂质过氧化药物中的应用。
8.权利要求1到5所述的任一提取物在制备抗动脉粥样硬化药物中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911332830.3A CN111012863A (zh) | 2019-12-24 | 2019-12-24 | 一种麦冬降解提取物及其在制备降糖药物中的应用 |
PCT/CN2019/128981 WO2021128232A1 (zh) | 2019-12-24 | 2019-12-27 | 一种麦冬降解提取物及其在制备降糖药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911332830.3A CN111012863A (zh) | 2019-12-24 | 2019-12-24 | 一种麦冬降解提取物及其在制备降糖药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111012863A true CN111012863A (zh) | 2020-04-17 |
Family
ID=70211434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911332830.3A Pending CN111012863A (zh) | 2019-12-24 | 2019-12-24 | 一种麦冬降解提取物及其在制备降糖药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111012863A (zh) |
WO (1) | WO2021128232A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112321738A (zh) * | 2020-11-02 | 2021-02-05 | 台州学院 | 一种抑制α-葡萄糖苷酶的青钱柳多糖制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943735A (zh) * | 2006-10-20 | 2007-04-11 | 中山大学 | 一种麦冬提取物的制备方法及其用途 |
CN101559166A (zh) * | 2009-05-26 | 2009-10-21 | 中山大学 | 一种麦冬提取物及其制备方法与降糖应用 |
CN102336931A (zh) * | 2011-10-25 | 2012-02-01 | 温州医学院 | 麦冬多糖及其制备方法和应用 |
CN102875689A (zh) * | 2012-10-09 | 2013-01-16 | 山东省医药工业研究所 | 一种麦冬多糖的制备方法及应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104371037A (zh) * | 2014-11-11 | 2015-02-25 | 常州大学 | 一种麦冬中麦冬多糖的提取方法 |
CN106798826B (zh) * | 2017-03-07 | 2020-07-07 | 中山大学 | 麦冬寡糖在制备促进棕色脂肪生成药物中的应用 |
-
2019
- 2019-12-24 CN CN201911332830.3A patent/CN111012863A/zh active Pending
- 2019-12-27 WO PCT/CN2019/128981 patent/WO2021128232A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943735A (zh) * | 2006-10-20 | 2007-04-11 | 中山大学 | 一种麦冬提取物的制备方法及其用途 |
CN101559166A (zh) * | 2009-05-26 | 2009-10-21 | 中山大学 | 一种麦冬提取物及其制备方法与降糖应用 |
CN102336931A (zh) * | 2011-10-25 | 2012-02-01 | 温州医学院 | 麦冬多糖及其制备方法和应用 |
CN102875689A (zh) * | 2012-10-09 | 2013-01-16 | 山东省医药工业研究所 | 一种麦冬多糖的制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
许定舟等: "不同分子量麦冬寡糖体外抑制α-葡萄糖苷酶活性的研究", 《中国热带医学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112321738A (zh) * | 2020-11-02 | 2021-02-05 | 台州学院 | 一种抑制α-葡萄糖苷酶的青钱柳多糖制备方法 |
CN112321738B (zh) * | 2020-11-02 | 2022-05-24 | 台州学院 | 一种抑制α-葡萄糖苷酶的青钱柳多糖制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2021128232A1 (zh) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768152B (zh) | 桂花苯乙醇苷提取物及其制备方法和用途 | |
CN111012863A (zh) | 一种麦冬降解提取物及其在制备降糖药物中的应用 | |
CN113789214A (zh) | 改善癌因性疲乏的复方灵芝孢子油及其制备方法和应用 | |
CN111248440B (zh) | 一种功能性茉莉花低聚糖口服液及其应用 | |
CN102525901A (zh) | 兽用党参多糖口服液及其制备方法 | |
CN103342755A (zh) | 枸杞多糖均一级份ⅳ及其制备方法和应用 | |
CN114292346B (zh) | 一种茯苓总多糖及其提取方法与应用 | |
CN110964126A (zh) | 一种麦冬降解提取物及其在制备防治心血管药物中的应用 | |
CN1264529C (zh) | 一种制备注射用参芪扶正冻干粉针剂的方法 | |
CN105920051B (zh) | 一种金针菇提取物及其制备方法与应用 | |
CN115998781A (zh) | 一种桦树汁分离液在治疗痛风中的应用 | |
CN106822228B (zh) | 一种山豆根多糖有效部位及其制备方法 | |
CN101129440A (zh) | 藏药大花红景天多糖降糖肠溶微丸及制备方法 | |
CN101332220A (zh) | 从天然植物番薯藤中提取分离薯藤多糖的制备方法 | |
CN106728962B (zh) | 一种增强免疫力的药物组合物及其应用 | |
CN101185662A (zh) | 从肾蕨中制备的用于治疗糖尿病新药的方法和用途 | |
CN109021135A (zh) | 一种素花党参多糖制剂及其制备方法 | |
CN101966251B (zh) | 一种用于预防及治疗支气管哮喘的药物组合物及其制备与应用 | |
CN113476497B (zh) | 一种具有抗hsv活性的夏枯草提取物及其制备方法和医药用途 | |
CN102698096B (zh) | 一种中药提取物的组合物及其制备方法和用途 | |
CN104586980B (zh) | 一种具有降血脂、降血糖作用的石楠叶红色素软胶囊及其制备方法 | |
CN1285355C (zh) | 清开灵冻干粉制剂的制备方法 | |
CN116327816A (zh) | 藜麦提取物及其提取方法和用途 | |
CN105250919B (zh) | 一种用于预防和/或治疗肝疾病的中药组合物及其制备方法 | |
CN117883466A (zh) | 一种具有降尿酸作用的多糖及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200417 |